Using the skindex-16 and common terminology criteria for adverse events to assess rash symptoms: Results of a pooled-analysis (N0993)

Supportive Care in Cancer

Volumn 20, Issue 8, 2012, Pages 1729-1735

  Atherton, Pamela J ^a   Burger, Kelli N ^a   Loprinzi, Charles L ^a   Wittich, Michelle A Neben ^a   Miller, Robert C ^a   Jatoi, Aminah ^a   Sloan, Jeff A ^a  

^a MAYO CLINIC   (United States)

Author keywords

CTCAE; Cytotoxic treatment induced dermatitis; Dermatitis; Patient reported outcomes; Skindex 16

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; MOMETASONE FUROATE; PLACEBO; SUNSCREEN; TETRACYCLINE;

ADULT; ADVERSE DRUG REACTION; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DATA ANALYSIS; DISEASE SEVERITY; DRUG ERUPTION; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NATIONAL CANCER INSTITUTE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIATION DERMATITIS; RASH; RATING SCALE; SCORING SYSTEM; SKIN TOXICITY; SKINDEX 16; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT DURATION;

ALGORITHMS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; EXANTHEMA; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PREGNADIENEDIOLS; PROTEIN KINASE INHIBITORS; PROTEIN SYNTHESIS INHIBITORS; QUESTIONNAIRES; QUINAZOLINES; RADIODERMATITIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SUNSCREENING AGENTS; TERMINOLOGY AS TOPIC; TETRACYCLINE;

EID: 84863980805     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-011-1266-x     Document Type: Article

References (19)

1. Hopewell JW (1990) The skin: its structure and response to ionizing radiation. Int J of Radiation Biol 57:751-773
2. Fu KK, Pajak TF, Trotti A et al (2000) A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Rad Oncol Biol Phys 48:7-16
3. Archambeau JO, Pezner R, Wasserman T (1995) Pathophysiology of irradiated skin and breast. Int J Rad Oncol Biol Phys 31:1171-1185
4. Herbst RS, Maddox A-M, Rothenberg ML et al (2002) Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well tolerated and has activity in non-small cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 20:3815-3825
5. Kris M, Natale RB, Herbst RS et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. J Am Med Assoc 290:2149-2158
6. Saltz LB, Meropol NJ, Loehrer PJ et al (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208
7. Cancer Therapy Evaluation Program NCI. Common Terminology Criteria for Adverse events (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic- applications/ctc.htm. Accessed 02 August 2010
8. Lacouture ME, Maitland ML, Sagaert S et al (2010) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity group. Support Care Cancer 18:509-522
9. Huschka MM, Mandrekar SJ, Schaefer PL et al (2007) A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trials. Cancer 109(4):787-795
10. Chren MM, Lasek RJ, Sahay AP et al (2001) Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 5(2):105-110
11. Huschka MM, Burger KN (2006) Does QOL provide the same information as toxicity data. Curr Probl Cancer 30(6):244-254
12. Basch E (2009) Patient-reported outcomes in drug safety evaluation. Ann Oncol 20:1905-1906
13. Parliament MB, Danjoux CE, Clayton T (1985) Is cancer treatment toxicity accurately reported? Int J Rad Oncol Biol Phys 11(3):603-608
14. Miller RC, Schwartz DJ, Sloan JA, Griffin PC, Deming RL, Anders JC, Stoffel TJ, Haselow RE, Schaefer PL, Bearden JD, Atherton PJ, Loprinzi CL, Martenson JA (2011) Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase 3 double-blind, randomized trial from the North Central Cancer Treatment Group N06C4. Int J Radiat Oncol Biol Phys 79:1460-1466
15. Jatoi A, Rowland KM, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, Novotny PJ, Schaefer PL, Johnson DB, Tschetter LK, Loprinzi CL (2008) Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebocontrolled trial from the NCCTG (N03CB). Cancer 113:847-853
16. Jatoi A (2007) Sunshine and rash: testing the role of sunscreen to prevent epidermal growth factor receptor inhibitor-induced rash. Support Cancer Therapy 4:198-202
17. Neben-WittichMA, Atherton PJ, Schwartz DJ, Sloan JA, Griffin PC, Deming RL, Anders JC, Loprinzi CL, Burger KN, Martenson JA, Miller RC (2011) Comparison of provider-assessed and patientreported outcome measures of acute skin toxicity during a phase III trial ofmometasone creamversus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4). Int J Radiat Oncol Biol Phys 81:397-402
18. National Cancer Institute, Division of Cancer Control and Population Sciences. Patient-Reported Outcomes Version of the ommon Terminology Criteria for Adverse events (PROCTCAE). http://outcomes.cancer.gov/tools/pro-ctcae-fact- sheet.pdf. Accessed August 2, 2010
19. Trotti A, Colevas AD, Setser A, Basch E (2007) Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 25(32):5121-5127